{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:38:15Z","timestamp":1793968695258,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In cervical screening, human papillomavirus (HPV)-positive women at 1-year retesting are typically referred to colposcopy. This study, by the use of extended genotyping, estimates the impact of distinguishing persistent from new infections in an effort to reduce colposcopy referral. It also evaluates whether the new infection rate varies according to genotyping, cytology, p16\/ki67, and E6\/E7 mRNA results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data from HPV-DNA-positive women at baseline in the NTCC2 trial genotyped with the Onclarity HPV assay. Eligible participants were Onclarity-positive women without baseline CIN2+ who had a cervicovaginal sample collected at least 10 months after baseline. Persistent infections were defined as cases with at least one common genotype between baseline and follow-up specimens. New infections were defined as cases positive for different genotypes at follow-up, with no baseline genotypes detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1,540 women included, 613 were Onclarity-positive at both baseline and 1-year retesting: 488 (79.6%) had persistent infections, while 68 (11.1%) had new ones. All the 11 CIN3 cases identified at follow-up occurred in women with persistent infections. The new infection rate was significantly higher in women with baseline single-channel compared to multiple channels positivity (13.3%\n                      <jats:italic>vs<\/jats:italic>\n                      5.5%, p=0.001). Stratifying by age, persistence and new infection rates were significantly different among different age groups (respectively p=0.005 and p=0.009). No significant difference in both new infections and persistence rate was observed between baseline cytology positive and negative cases. Stratifying by baseline p16\/ki67 results, we found a significantly higher rate of persistent cases among p16\/ki67 positive cases and of new infections among p16\/ki67 negative cases (respectively p=0.013 and p=0.016). E6\/E7 mRNA findings affected only persistence rate showing a significant difference in the proportion of persistent cases between positive and negative cases (p=0.004), but did not affect new infection rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Extended genotyping classified 11.5% of 1-year HPV-positive cases as new infections. As 1-year HPV positivity accounts for about 60% of first-level colposcopies, this corresponds to about 7% of colposcopies. Baseline single-channel positivity, age, and p16\/ki67-negative results may influence this proportion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov registration number: NCT01837693, New Technology in Cervical Cancer 2 (NTCC2) study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13027-025-00713-8","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:03:15Z","timestamp":1763596995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 study"],"prefix":"10.1186","volume":"20","author":[{"given":"Annarosa","family":"Del Mistro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Bisanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Pompeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Allia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gustinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Frayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Iossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cesarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Bulletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Toniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Giorgi Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NTCC2 Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"713_CR1","doi-asserted-by":"crossref","unstructured":"Ronco G, Arbyn M, Meijer CJ, Snijeders P, Cuzick J. Screening for cervical cancer with primary testing for human papillomavirus. In: Anttila A, Arbyn M, De Vuyst H, et al. editors. European guidelines for quality assurance in cervical cancer screening. Supplement. Second ed. Luxembourg: Office for Official Publications of the European Union; 2015. p. 1\u201368.","DOI":"10.1016\/j.pvr.2015.06.006"},{"key":"713_CR2","unstructured":"Who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd. Geneva; 2021."},{"issue":"Suppl 1(Suppl 1","key":"713_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","volume":"76","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(Suppl 1(Suppl 1)):S49\u201355. https:\/\/doi.org\/10.1016\/j.jcv.2015.11.015.","journal-title":"J Clin Virol"},{"issue":"3","key":"713_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jnci\/djaa105","volume":"113","author":"P Giorgi Rossi","year":"2021","unstructured":"Giorgi Rossi P, Carozzi F, Ronco G, Allia E, Bisanzi S, Gillio-Tos A, De Marco L, Rizzolo R, Gustinucci D, Del Mistro A, Frayle H, Confortini M, Iossa A, Cesarini E, Bulletti S, Passamonti B, Gori S, Toniolo L, Barca A, Bonvicini L, Mancuso P, Venturelli F, Benevolo M, the New Technology for Cervical Cancer 2 Working Group. p16\/ki67 and E6\/E7 mRNA accuracy and prognostic value in triaging HPV DNA-Positive women. J Natl Cancer Inst. 2021;113(3):292\u2013300. https:\/\/doi.org\/10.1093\/jnci\/djaa105.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"713_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cncy.22103","volume":"127","author":"E Peeters","year":"2019","unstructured":"Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis ofthe accuracy of p16 or p16\/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+\/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol. 2019;127(3):169\u201380. https:\/\/doi.org\/10.1002\/cncy.22103.","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"713_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","volume":"179","author":"N Wentzensen","year":"2019","unstructured":"Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD, Grewal KK, Locke A, Kinney W, Lorey TS. Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med. 2019;179(7):881\u201388. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0306.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"713_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/LGT.0000000000000706","volume":"27","author":"M El-Zein","year":"2023","unstructured":"El-Zein M, Bouten S, Abdrabo LS, Siblini A, Louvanto K, Franco E, Ferenczy A. Genotyping and cytology triage of high-risk HPV dna positive women for detection of cervical high-grade lesions. J Low Genit Tract Dis. 2023;27(1):12\u201318. https:\/\/doi.org\/10.1097\/LGT.0000000000000706.","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"713_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ijc.33320","volume":"148","author":"J Bonde","year":"2021","unstructured":"Bonde J, Floore A, Ejegod D, Vink FJ, Hesselink A, van de Ven Pm, Ao V, Pedersen H, Doorn S, Quint WG, Petry KU, Poljak M, Stanczuk G, Cuschieri K, de Sanjos\u00e9 S, Bleeker M, Berkhof J, Cjlm M, Heideman DAM. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int. J. Cancer. 2021;148(2):396\u2013405. https:\/\/doi.org\/10.1002\/ijc.33320.","journal-title":"Int. J. Cancer"},{"key":"713_CR9","doi-asserted-by":"publisher","unstructured":"Kj\u00e6r SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102(19):1478\u201388. https:\/\/doi.org\/10.1093\/jnci\/djq356.","DOI":"10.1093\/jnci\/djq356"},{"key":"713_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/1471-2334-13-373","volume":"13","author":"E Bernard","year":"2013","unstructured":"Bernard E, Pons-Salort M, Favre M, Heard I, Delarocque-Astagneau E, Guillemot D, Thi\u00e9baut AC. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies. BMC Infect Dis. 2013;13:373. https:\/\/doi.org\/10.1186\/1471-2334-13-373.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"713_CR11","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/ijc.31883","volume":"144","author":"FL Sand","year":"2019","unstructured":"Sand FL, Munk C, Frederiksen K, Junge J, Iftner T, Dehlendorff C, Kjaer SK. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int. J. Cancer. 2019;144(8):1975\u201382. https:\/\/doi.org\/10.1002\/ijc.31883.","journal-title":"Int. J. Cancer"},{"issue":"1","key":"713_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/LGT.0000000000000573","volume":"25","author":"J Bonde","year":"2021","unstructured":"Bonde J, Bottari F, Iacobone AD, Cocuzza CE, Sandri MT, Bogliatto F, Khan KS, Ejegod DM, Gary DS, Andrews JC. Human papillomavirus same genotype persistence and risk: a systematic review. J Low Genit Tract Dis. 2021;25(1):27\u201337. https:\/\/doi.org\/10.1097\/LGT.0000000000000573.","journal-title":"J Low Genit Tract Dis"},{"key":"713_CR13","first-page":"1","volume":"18","author":"IARC Handbook 2021: IARC","year":"2022","unstructured":"IARC Handbook 2021: IARC. Cervical cancer screening. IARC Handb Cancer Prev. 2022;18:1\u2013456. Available from: https:\/\/publications.iarc.fr\/604.","journal-title":"IARC Handb Cancer Prev"},{"issue":"10","key":"713_CR14","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ijc.27485","volume":"131","author":"P Guan","year":"2012","unstructured":"Guan P, Howell-Jones R, Li N, Bruni L, de Sanjos\u00e9 S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer. 2012;131(10):2349\u201359. https:\/\/doi.org\/10.1002\/ijc.27485. PMID:22323075.","journal-title":"Int. J. Cancer"},{"issue":"3","key":"713_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/AOG.0000000000003409","volume":"134","author":"F Bottari","year":"2019","unstructured":"Bottari F, Iacobone AD, Passerini R, Preti EP, Sandri MT, Cocuzza CE, Gary DS, Andrews JC. Human papillomavirus genotyping compared with a qualitative high-risk human papillomavirus test after treatment of high-grade cervical intraepithelial neoplasia: a systematic review. Obstet Gynecol. 2019;134(3):452\u201362. https:\/\/doi.org\/10.1097\/AOG.0000000000003409.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"713_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","volume":"24","author":"JH Bonde","year":"2020","unstructured":"Bonde JH, Sandri M, Gary DS, Andrews JC. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J Low Genit Tract Dis. 2020;24(1):1\u201313. https:\/\/doi.org\/10.1097\/LGT.0000000000000494.","journal-title":"J Low Genit Tract Dis"},{"key":"713_CR17","unstructured":"Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Tornberg S, von Karsa L. In: European guidelines for quality assurance in cervical cancer screening. Luxembourg: Publications Office; 2015."},{"key":"713_CR18","doi-asserted-by":"publisher","unstructured":"Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M. ASCCP risk-based management consensus guidelines committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2019. 2020;24(2):102\u201331. https:\/\/doi.org\/10.1097\/LGT.0000000000000525.","DOI":"10.1097\/LGT.0000000000000525"},{"key":"713_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2016.09.008","volume":"68","author":"G Ronco","year":"2016","unstructured":"Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, Del Mistro A, Carozzi F, Segnan N, Zorzi M, Giorgi-Rossi P, Italian HPV Survey Working Group. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms. Eur J Cancer. 2016, Nov;68:148\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.008. Epub 2016 Oct 15. PMID: 27755998.","journal-title":"Eur J Cancer"},{"key":"713_CR20","doi-asserted-by":"publisher","first-page":"b2569","DOI":"10.1136\/bmj.b2569","volume":"339","author":"PE Castle","year":"2009","unstructured":"Castle PE, Rodr\u00edguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D, Schiffman M; Proyecto Epidemiol\u00f3gico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009;339:b2569. https:\/\/doi.org\/10.1136\/bmj.b2569.","journal-title":"BMJ"},{"issue":"10","key":"713_CR21","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1128\/JCM.01366-15","volume":"53","author":"K Cuschieri","year":"2015","unstructured":"Cuschieri K, Geraets DT, Moore C, Quint W, Duvall E, Arbyn M. Clinical and analytical performance of the onclarity HPV assay using the VALGENT framework. J Clin Microbiol. 2015;53(10):3272\u201379. https:\/\/doi.org\/10.1128\/JCM.01366-15.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"713_CR22","doi-asserted-by":"publisher","first-page":"e01518","DOI":"10.1128\/JCM.01518-19","volume":"58","author":"JH Bonde","year":"2020","unstructured":"Bonde JH, Pedersen H, Quint W, Xu L, Arbyn M, Ejegod DM. Clinical and analytical performance of the bd onclarity HPV assay with SurePath screening samples from the Danish cervical screening program using the VALGENT framework. J Clin Microbiol. 2020;58(2):e01518\u201319. https:\/\/doi.org\/10.1128\/JCM.01518-19.","journal-title":"J Clin Microbiol"},{"key":"713_CR23","doi-asserted-by":"publisher","first-page":"e0089724","DOI":"10.1128\/spectrum.00897-24","volume":"13","author":"L De Marco","year":"2025","unstructured":"De Marco L, Bisanzi S, Ronco G, Mancuso P, Carozzi F, Allia E, Rizzolo R, Gustinucci D, Frayle H, Viti J, Iossa A, Cesarini E, Bulletti S, Passamonti B, Gori S, Toniolo L, Venturelli F, Del Mistro A, Giorgi Rossi P, Benevolo M, NTCC2 Working Group. Extended HPV genotyping by the bd onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study. Microbiol Spectr. 2025;13:e0089724. https:\/\/doi.org\/10.1128\/spectrum.00897-24.","journal-title":"Microbiol Spectr"},{"key":"713_CR24","doi-asserted-by":"publisher","first-page":"105149","DOI":"10.1016\/j.ebiom.2024.105149","volume":"104","author":"M Benevolo","year":"2024","unstructured":"Benevolo M, Ronco G, Mancuso P, Carozzi F, De Marco L, Allia E, Bisanzi S, Rizzolo R, Gustinucci D, Del Mistro A, Frayle H, Confortini M, Viti J, Iossa A, Cesarini E, Bulletti S, Passamonti B, Gori S, Toniolo L, Bonvicini L, Venturelli F, Wentzensen N, Giorgi Rossi P, NTCC2 Working Group. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16\/ki67 dual staining in the Italian NTCC2 study. EBioMedicine. 2024, Jun;104:105149. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105149. Epub 2024 May 17. PMID: 38759278; PMCID: PMC11126882.","journal-title":"EBioMedicine"},{"key":"713_CR25","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","volume":"2","author":"M Schiffman","year":"2016","unstructured":"Schiffman M, Doorbar J, Wentzensen N, de Sanjos\u00e9 S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086. https:\/\/doi.org\/10.1038\/nrdp.2016.86.","journal-title":"Nat Rev Dis Primers"},{"key":"713_CR26","unstructured":"https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/livmoderhalscancerprevention\/vardprogram\/kolposkopi-och-utredning-av-avvikande-cellprov\/."},{"key":"713_CR27","unstructured":"https:\/\/www.rivm.nl\/en\/cervical-cancer-screening-programme."},{"key":"713_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03161-8","author":"S Gori","year":"2025","unstructured":"Gori S, Venturelli F, Carozzi F, Giorgi Rossi P, Del Mistro A and on behalf of the Multisocietal Contributor Group. Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and grade methodology. Br J Cancer. 2025, Sep, 11. https:\/\/doi.org\/10.1038\/s41416-025-03161-8. Online ahead of print.","journal-title":"Br J Cancer"},{"issue":"11","key":"713_CR29","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/1471-0528.15893","volume":"126","author":"A Del Mistro","year":"2019","unstructured":"Del Mistro A, Giorgi Rossi P, Frayle H, Pasquale L, Campari C, Ronco G, Zorzi M. Five-year risk of CIN3 after short-term HPV-DNA negativity in cytology-negative women: a population-based cohort study. BJOG. 2019;126(11):1365\u201371. https:\/\/doi.org\/10.1111\/1471-0528.15893.","journal-title":"BJOG"},{"issue":"10","key":"713_CR30","doi-asserted-by":"publisher","first-page":"e1004115","DOI":"10.1371\/journal.pmed.1004115","volume":"19","author":"F Inturrisi","year":"2022","unstructured":"Inturrisi F, Rozendaal L, Veldhuijzen NJ, Heideman DAM, Cjlm M, Berkhof J. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: a follow-up analysis of a randomized screening study. PLoS Med. 2022;19(10):e1004115. https:\/\/doi.org\/10.1371\/journal.pmed.1004115.","journal-title":"PLoS Med"},{"issue":"10","key":"713_CR31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/bjc.2017.309","volume":"117","author":"NJ Polman","year":"2017","unstructured":"Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Cjlm M, Berkhof J. HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. Br J Cancer. 2017;117(10):1557\u201361. https:\/\/doi.org\/10.1038\/bjc.2017.309.","journal-title":"Br J Cancer"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-025-00713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-025-00713-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-025-00713-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:03:16Z","timestamp":1763596996000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-025-00713-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s13027-025-00713-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7045128\/v1","asserted-by":"object"}]},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NTCC2 study protocol was approved by the S. Giovanni Battista University Hospital, Turin, Italy, on 20 June 2012 (N. CEI513) and by the local committees of all recruiting centers. The present extension of the study protocol was approved by the Comitato Etico Centrale IRCCS Lazio, Fondazione G.B. Bietti, N 1153\/18, 20\/11\/2018. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Maria Benevolo, as principal investigator, and Paolo Giorgi Rossi, as former principal investigator of the NTCC2 study, report nonfinancial support from Roche Diagnostics and Hologic S.r.l., which provided part of the reagents for free or at reduced price. Moreover, Maria Benevolo, Paolo Giorgi Rossi, Simonetta Bisanzi, and Laura De Marco obtained financial and non-financial support from Becton&Dickinson for genotyping NTCC2 stored samples. The manufacturers did not influence the study design, conduction, or data analysis. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}